Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Merck KGaA’sMRK-1.94%decrease ... sales grow faster than previously expected over the medium term. The life-sciences and chemicals group lifted its mid-term outlook for its electronics business ...

GERMAN science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for US$600 million, it said ahead of its Capital ...